Skip to main content
Completed Research: PRACTICE MANAGEMENT RESEARCH
Abstract #CR01

Assessing Student Pharmacists’ Knowledge and Perceptions of Financial Toxicity Concepts Introduced in an Oncology Pharmacotherapy Course

JHOP - March 2024 Vol 14 Special Feature - HOPA Abstracts
Charles Wight, PharmD; Matthew DellaVecchia, PhD; Nicholas Chow, PharmD, BCOP; Monica Tadros, PharmD, BCPS, BCOP

Presenting Author: Charles Wight, PharmD, Palm Beach Atlantic University, West Palm Beach, FL

Co-Authors: Matthew DellaVecchia, PhD, and Nicholas Chow, PharmD, BCOP, Palm Beach Atlantic University, West Palm Beach, FL; Monica Tadros, PharmD, BCPS, BCOP, Miami Cancer Institute-Baptist Health South Florida, Miami, FL

BACKGROUND: Current, standard pharmacy school oncology curricula thoroughly discuss treatment toxicities and patient education. As cancer treatment costs continue to rise, financial toxicity is an increasingly important component of patient education. A national survey of how pharmacy schools incorporate concepts of affordable medication options revealed that the concept of financial toxicity was not described within the context of oncology care. There is no current literature evaluating financial toxicity education within pharmacy oncology courses nor student pharmacists’ knowledge of the concept.

OBJECTIVE: This survey-based study is designed to assess the impact of assigned reading material and lecture-based practice discussions on pharmacy students’ knowledge and perceptions of the concept of financial toxicity in cancer care during an oncology pharmacotherapeutics course.

METHODS: During an oncology pharmacotherapeutics course, a pre-lecture questionnaire was disseminated to students which assessed baseline student knowledge and perceptions of financial toxicity in cancer care. Students were assigned reading materials and participated in a formal lecture-based in-class discussion on the concept of financial toxicity and its implications in pharmacy practice. Students then completed a post-lecture questionnaire designed to assess changes in student knowledge and perceptions of financial toxicity as it relates to cancer care and treatment. The questionnaire consisted of Likert scale, multiple choice, and free response prompts to evaluate defining the concept, its role in cancer care, the resources available for patients, and the pharmacist’s role. All questionnaires were completed within 1 week surrounding the lecture discussions.

RESULTS: A total of 78 pharmacy students participated in the survey. Prior to instruction, 23 (29.5%) students agreed/strongly agreed that they could clearly define the term financial toxicity compared with 73 (93.6%) students post-instruction. In terms of being able to clearly define the role that financial toxicity plays in overall cancer and patient outcomes, 31 (39.7%) students agreed/strongly agreed pre-instruction compared with 71 (91.02%) students post-instruction. Regarding the knowledge of patient resources, 10 (12.8%) students agreed/strongly agreed pre-instruction compared with 55 (70.5%) students post-instruction. Regarding their opinion on the importance of the pharmacist’s role in managing financial toxicity, 65 (83.3%) students agreed/strongly agreed pre-instruction compared with 71 (91%) students post-instruction.

CONCLUSION: This study demonstrates the need for increased education on the concept of financial toxicity in oncology pharmacy curricula. It is important that pharmacy students are exposed to this during their coursework and have a basic understanding of financial toxicity on graduation. Based on this study, further financial concepts will be evaluated in this pharmacy school’s oncology curriculum.

  1. Ratain MJ. Biomarkers and Clinical Care. Presented at the AAAS/FDLI Colloquium, Personalized Medicine in an Era of Health Care Reform; Washington, DC; October 27, 2009. http://shr01.aaas.org/projects/personalized_ med/colloquia/ppts/Ratain.pdf
  2. Hussaini SMQ, Gupta A, Dusetzina SB. Financial toxicity of cancer treatment. JAMA Oncol. 2022;8:788.
  3. Ramsey S, Blough D, Kirchhoff A, et al. Washington state cancer patients found to be at greater risk for bankruptcy than people without a cancer diagnosis. Health Aff (Millwood). 2013;32:1143-1152.
  4. Zafar SY, Peppercorn JM, Schrag D, et al. The financial toxicity of cancer treatment: a pilot study assessing out-of-pocket expenses and the insured cancer patient’s experience. Oncologist. 2013;18:381-390.
  5. Ramsey SD, Bansal A, Fedorenko CR, et al. Financial insolvency as a risk factor for early mortality among patients with cancer. J Clin Oncol. 2016;34:980-986.
  6. Richey-Smith C, Burgess J, Mehringer E. Affordable drug options: a survey of what colleges and schools of pharmacy are teaching. Currents in Pharmacy Teaching and Learning. 2011;3:208-21
Related Items
Optimizing Iron Dextran Infusion Protocols to Enhance Efficiency and Patient Throughput in an Outpatient Infusion Center: A Process Improvement Initiative
JHOP - March 2025 Vol 15 Special Feature published on March 12, 2025 in HOPA Abstracts
Characteristics and Dosing Patterns of US Patients Diagnosed With HR-Positive/HER2-Negative Early Breast Cancer Initiating Abemaciclib at a Lower Dose Than the Approved 150 mg Twice Daily
JHOP - March 2025 Vol 15 Special Feature published on March 12, 2025 in HOPA Abstracts
Clinical Characteristics and Treatment Persistence in US Patients With HR-Positive/HER2-Negative, Node-Positive Early Breast Cancer Treated With Abemaciclib: Real-World Study From First Year After Approval
JHOP - March 2025 Vol 15 Special Feature published on March 12, 2025 in HOPA Abstracts
Clinical Outcomes of 2-Dose Tandem Influenza Vaccination Strategy in Patients With Plasma Cell Dyscrasias
JHOP - March 2025 Vol 15 Special Feature published on March 12, 2025 in HOPA Abstracts
Dexamethasone Versus Tocilizumab for Management of Cytokine Release Syndrome Related to Teclistamab in Patients With Relapsed/Refractory Multiple Myeloma
JHOP - March 2025 Vol 15 Special Feature published on March 12, 2025 in HOPA Abstracts
Evaluating the Impact of Interactive Ambulatory Care Discussions at an Oncology Center
JHOP - March 2025 Vol 15 Special Feature published on March 12, 2025 in HOPA Abstracts
Evaluation of a Decentralized Infusion Pharmacist in an Oncology Infusion Clinic of an Academic Medical Center
JHOP - March 2025 Vol 15 Special Feature published on March 12, 2025 in HOPA Abstracts
Evaluation of Reduced Observation Times for Subcutaneous Administration of Daratumumab and Hyaluronidase in Patients With Multiple Myeloma
JHOP - March 2025 Vol 15 Special Feature published on March 12, 2025 in HOPA Abstracts
Evaluation of Services Provided by Pharmacists in Addition to Accredited Patient Management Program Responsibilities in a Health-System Specialty Pharmacy
JHOP - March 2025 Vol 15 Special Feature published on March 12, 2025 in HOPA Abstracts
Hematologic Oral Oncolytics: Adherence, Healthcare Cost, and Utilization
JHOP - March 2025 Vol 15 Special Feature published on March 12, 2025 in HOPA Abstracts